Table 1

Effect of squalamine and cisplatin or paclitaxel plus carboplatin on the growth of the MV-522 human lung tumor xenograft in nude mice

Each treatment group consisted of 10 mice. The percentage TGI was calculated using the final mean excised tumor weight for each treatment group rather than the final tumor weights estimated by dimensional measurement. The squalamine dose as listed was administered on a daily basis as a split dose.
GroupDose (mg/kg/day)Route & scheduleBody weight change (day 24)Final excised tumor weight (mg; mean ± SE) (TGI)% TGIMice with partial shrinkageMean % tumor shrinkageNo. of toxic deaths
ControlVehiclei.p.: b.i.d. days 1–5, 8–9+4.3%758.6 ± 103.500
Squalamine20i.p.: b.i.d. days 1–5, 8–9+5.3%613.6 ± 64.628.6%00
Cisplatin2.0i.p.: q.d. × 5a+7.9%218.7 ± 44.273.3%241.6%0
Squalamine20i.p.: b.i.d. days 1–5, 8–9
 + cisplatin2.0i.p.: q.d. × 5−0.9%105.0 ± 28.686.9%345.1%3
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5+7.0%365.9 ± 66.060.3%00
Paclitaxel10i.p.: q.d. × 5
 + carboplatin20i.p.: q.d. × 5
 + squalamine20i.p.: b.i.d. days 1–5, 8–9+0.0%56.4 ± 14.596.1%454.8%3
  • a Days 1–5, 8–9 refers to dosing on days 1 through 5 and 8 through 9, inclusive, after initiating chemotherapeutic treatment.

  • b ×5, for 5 days.